drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Injectable bispecific T‑cell–engaging antibody that binds GPRC5D on myeloma plasma cells and CD3 on T cells to activate TCR/CD3 signaling and redirect cytotoxic T cells to kill GPRC5D-positive malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific T-cell–engaging antibody that binds GPRC5D on myeloma cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect cytotoxic T cells to kill GPRC5D-positive malignant plasma cells via perforin/granzyme release.
drug_name
TQB2029
nct_id_drug_ref
NCT06700395